Compare ACADIA Pharmaceuticals Inc. (ACAD) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs MobilEye Global Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.76 (market cap $5.07B), while MobilEye Global Inc trades at $8.76 (market cap $7.54B). The key difference: MobilEye Global Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | MBLY | |
|---|---|---|
Market Cap | $5.07B | $7.54B |
Sector | Health | Technology |
52-Week High | $29.41 | $15.54 |
52-Week Low | $20.06 | $6.56 |
Enterprise Value | $4.19B | $6.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Mobileye Global Inc. (MBLY) trades at $8.81, up 0.69% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings beats, driven by an R&D grant, though it remains unprofitable with a net income margin of -201.49%. Recent news highlights CEO transition plans and a new supply deal with Stellantis, while analyst consensus is bullish with a $11.40 price target.
The outlook is mixed: raised 2026 guidance and strategic partnerships offer growth potential in autonomous driving, but persistent losses, leadership changes, and high valuation multiples pose significant risks. Investors should weigh the company's technological positioning against its current financial health and execution challenges in a competitive market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
